ANPEP and metabolic disease: The association between cardiometabolic disorders and hypo-adiponectinemia is well-documented [27,28,29,30], and many specialists suggest that the discovery of APN receptor agonists and/or APN modulators represents a big step towards preventing and, eventually, reversing the course of metabolic disorders associated with APN deficiency [31,32,33,34,35].